Figure 2.
Figure 2. Relative percentage of various cytogenetic abnormalities in de novo myelodysplastic syndrome (MDS). / Cytogenetic abnormalities are found in 40%–70% of patients with de novo MDS and nearly 95% of patients with therapy-related MDS. This chart illustrates the relative distribution of the most common cytogenetic abnormalities in de novo MDS. / Percentage of WHO subtypes showing cytogenetic abnormalities: refractory anemia 24%, refractory anemia with ringed sideroblasts (RARS) 29%, refractory anemia with excess blasts–1 (RAEB-1) 35%, refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) 37%, refractory anemia with excess blasts–2 (RAEB-2) 38%.

Relative percentage of various cytogenetic abnormalities in de novo myelodysplastic syndrome (MDS).

Cytogenetic abnormalities are found in 40%–70% of patients with de novo MDS and nearly 95% of patients with therapy-related MDS. This chart illustrates the relative distribution of the most common cytogenetic abnormalities in de novo MDS.

Percentage of WHO subtypes showing cytogenetic abnormalities: refractory anemia 24%, refractory anemia with ringed sideroblasts (RARS) 29%, refractory anemia with excess blasts–1 (RAEB-1) 35%, refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) 37%, refractory anemia with excess blasts–2 (RAEB-2) 38%.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal